{"id":"fulvestrant-combined-with-pyrotinib","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Decreased appetite"}]},"_chembl":{"chemblId":"CHEMBL3647420","moleculeType":"Small molecule","molecularWeight":"583.09"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fulvestrant is a selective estrogen receptor degrader (SERD) that competitively binds to the estrogen receptor and promotes its degradation, eliminating estrogen-driven proliferation in hormone receptor-positive breast cancers. Pyrotinib is a pan-HER tyrosine kinase inhibitor that irreversibly blocks HER1, HER2, and HER4 signaling. This combination addresses tumors with both hormone receptor and HER2 dependency, potentially overcoming resistance mechanisms in advanced breast cancer.","oneSentence":"Fulvestrant blocks estrogen receptor signaling while pyrotinib inhibits HER2 tyrosine kinase, together targeting hormone receptor-positive and HER2-positive breast cancer through dual pathway inhibition.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:32.355Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive, hormone receptor-positive metastatic or advanced breast cancer"}]},"trialDetails":[{"nctId":"NCT07179939","phase":"PHASE2","title":"Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-10","conditions":"HER2-positive Breast Cancer","enrollment":288},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT06208410","phase":"PHASE1, PHASE2","title":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Risen (Suzhou) Pharma Tech Co., Ltd.","startDate":"2024-01-11","conditions":"Advanced Solid Tumors","enrollment":306},{"nctId":"NCT05328440","phase":"PHASE2","title":"Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2022-05-20","conditions":"Breast Neoplasms","enrollment":120},{"nctId":"NCT03772353","phase":"PHASE1, PHASE2","title":"Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-05-12","conditions":"Breast Cancer","enrollment":59},{"nctId":"NCT05577923","phase":"PHASE2","title":"Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-11-01","conditions":"Metastatic Breast Cancer","enrollment":126},{"nctId":"NCT04355858","phase":"PHASE2","title":"Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-05-01","conditions":"Breast Cancer, Metastatic Cancer","enrollment":319},{"nctId":"NCT04334330","phase":"PHASE2","title":"Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-12-04","conditions":"Breast Cancer, Brain Metastases","enrollment":34},{"nctId":"NCT04034589","phase":"PHASE2","title":"Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2019-07-17","conditions":"Metastatic Breast Cancer","enrollment":46},{"nctId":"NCT04646759","phase":"PHASE3","title":"Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2020-10-14","conditions":"Breast Cancer","enrollment":516}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FASLODEX combined with Pyrotinib"],"phase":"phase_3","status":"active","brandName":"Fulvestrant combined with Pyrotinib","genericName":"Fulvestrant combined with Pyrotinib","companyName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","companyId":"sun-yat-sen-memorial-hospital-of-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fulvestrant blocks estrogen receptor signaling while pyrotinib inhibits HER2 tyrosine kinase, together targeting hormone receptor-positive and HER2-positive breast cancer through dual pathway inhibition. Used for HER2-positive, hormone receptor-positive metastatic or advanced breast cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}